To validate the predictive ability of RPM for immunotherapy response, we calculated RPM scores in GSE78220 (28 melanoma patients treated with anti-PD-1 inhibitor), GSE91061 (105 melanoma patients treated with anti-PD-1 inhibitor), and Liu’s cohort (121 melanoma patients treated with anti-PD-1 inhibitor). This evidence concerns the gene PDCD1 and melanoma.